Insigneo Advisory Services LLC Makes New $362,000 Investment in Humana Inc. (NYSE:HUM)

Insigneo Advisory Services LLC bought a new stake in Humana Inc. (NYSE:HUM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,015 shares of the insurance provider’s stock, valued at approximately $362,000.

Other large investors have also modified their holdings of the company. Pzena Investment Management LLC increased its stake in Humana by 538.7% in the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after buying an additional 1,955,375 shares during the period. Davis Selected Advisers increased its stake in shares of Humana by 16.1% during the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after acquiring an additional 321,233 shares during the period. Marshall Wace LLP raised its holdings in Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its position in Humana by 11,647.2% in the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after purchasing an additional 1,050,459 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Humana by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,018,248 shares of the insurance provider’s stock valued at $380,368,000 after purchasing an additional 20,891 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Up 2.1 %

Shares of NYSE HUM opened at $319.52 on Friday. The firm has a market cap of $38.50 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The firm’s 50 day moving average price is $351.30 and its 200 day moving average price is $344.65.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm earned $8.94 earnings per share. As a group, sell-side analysts anticipate that Humana Inc. will post 16.01 earnings per share for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio is currently 22.04%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Friday, September 20th. Oppenheimer raised their target price on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. boosted their target price on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research note on Friday, August 2nd. Finally, Truist Financial upped their target price on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, July 15th. Thirteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average price target of $398.70.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.